

## **MBS Inks Deal with Canon BioMedical for NEXTGENPCR distribution in US and Canada**

### **Partnership rapidly provides NEXTGENPCR to US and Canadian customers**

Amsterdam, April 23rd 2018: Dutch biotechnology company Molecular Biology Systems (MBS) today announced it will launch its revolutionary NEXTGENPCR thermal cycler in the US and Canada through Canon BioMedical, Inc., a wholly owned subsidiary of Canon U.S.A., Inc. focused on empowering the biomedical research and healthcare communities by developing, manufacturing, and marketing innovative technologies and solutions.

According to the latest surveys, the global life sciences instrumentation market continues to grow at a CAGR of 8.2% and is predicted to be worth \$85.1 billion by 2022. The US and Canada account for the largest share, fueled by a rapid adoption rate of novel technologies, the large number of life science research studies conducted in the region, and increased funding for life science research activities.

Canon BioMedical has established itself in the market since the launch of its Novallele™ genotyping assays in September 2015. “We’ve successfully penetrated a wide variety of research areas, such as pharmacogenetics, cancer, and inherited disease. Time to result is a constant concern for laboratorians, and we immediately saw an advantage in incorporating NEXTGENPCR as part of our portfolio,” says Dennis Snyder, Senior Director of Global Commercial Operations for Canon BioMedical. “We are, therefore, delighted to secure this collaboration and look forward to rolling out NEXTGENPCR in the US and Canada to both existing and new customers.” Described as the first real advance in thermal cycling for 15 years, the NEXTGENPCR dramatically slashes current time-consuming DNA amplification from hours to minutes. For example, a 3-step, 30-cycle protocol can be performed in less than 2 minutes. SBS Standard format 96- or 384-well microplates are used, making incorporation into existing laboratory routines and protocols seamless. NEXTGENPCR delivers these astonishing times by turning existing technology on its head. Instead of heating and cooling Peltier blocks, NEXTGENPCR cleverly moves standard format microplates rapidly across 3 temperature zones already set to the required denaturing, extension and annealing temperatures.

The microplate samples are embedded in a polypropylene sheet and slightly compressed by the temperature blocks in each zone which ensures thorough sample mixing and optimal heat transfer. Well-to-well uniformity across the block is better than 0.1 °C. Temperature transition is practically instantaneous with a total reaction time of 2 minutes. This results in a dramatic reduction in power consumption when compared to traditional heating block methods.

“Entering the US and Canadian markets is a key part of our strategy,” says MBS CEO and founder, Gert de Vos. “We have been impressed with Canon BioMedical’s rapid growth and continuing ambition and are therefore delighted to have them as our launch partner.”

**For further information:**

Gert de Vos, CEO

[gertdevos@mbspcr.com](mailto:gertdevos@mbspcr.com)

[www.nextgenpcr.com](http://www.nextgenpcr.com)

**Media:**

Richard Hayhurst

[Richard@richardhayhurstassociates.com](mailto:Richard@richardhayhurstassociates.com)

**Notes to editors:**

Molecular Biology Systems (MBS) is a Netherlands-based molecular biology instrumentation company founded in 2015. The company’s lead product is the NEXTGENPCR thermal cycler which uses patented heating and cooling technology to reduce PCR amplification cycles from hours to minutes for both research and routine genetic testing. More at [www.nextgenpcr.com](http://www.nextgenpcr.com)